ZA9610543B - Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP. - Google Patents
Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP.Info
- Publication number
- ZA9610543B ZA9610543B ZA9610543A ZA9610543A ZA9610543B ZA 9610543 B ZA9610543 B ZA 9610543B ZA 9610543 A ZA9610543 A ZA 9610543A ZA 9610543 A ZA9610543 A ZA 9610543A ZA 9610543 B ZA9610543 B ZA 9610543B
- Authority
- ZA
- South Africa
- Prior art keywords
- cgrp
- inhibiting
- compositions
- activity
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK142695 | 1995-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA9610543B true ZA9610543B (en) | 1998-01-08 |
Family
ID=8104711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9610543A ZA9610543B (en) | 1995-12-15 | 1996-12-13 | Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5741791A (xx) |
| EP (1) | EP0869777A1 (xx) |
| JP (1) | JP3048067B2 (xx) |
| KR (1) | KR20000064411A (xx) |
| AR (1) | AR005075A1 (xx) |
| AU (1) | AU704825B2 (xx) |
| BR (1) | BR9612005A (xx) |
| CA (1) | CA2239487A1 (xx) |
| CZ (1) | CZ179598A3 (xx) |
| HU (1) | HUP9901652A3 (xx) |
| IL (1) | IL124557A0 (xx) |
| NO (1) | NO982732L (xx) |
| PL (1) | PL327445A1 (xx) |
| WO (1) | WO1997022338A1 (xx) |
| ZA (1) | ZA9610543B (xx) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110913A (en) * | 1994-01-04 | 2000-08-29 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
| US8321013B2 (en) * | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
| JP4175662B2 (ja) | 1996-01-08 | 2008-11-05 | インパルス ダイナミクス エヌ．ヴイ． | 電気的筋肉制御装置 |
| US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
| US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
| US7167748B2 (en) | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
| US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
| ZA978792B (en) * | 1996-10-04 | 1998-04-06 | Novo Nordisk As | N-substituted azaheterocyclic compounds. |
| US7006871B1 (en) | 1997-07-16 | 2006-02-28 | Metacure N.V. | Blood glucose level control |
| WO2000037081A1 (en) * | 1998-12-22 | 2000-06-29 | Novo Nordisk A/S | Novel formulation |
| US6207682B1 (en) | 1998-12-22 | 2001-03-27 | Novo Nordisk A/S | Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid |
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| WO2006073671A1 (en) * | 2004-12-09 | 2006-07-13 | Impulse Dynamics Nv | Protein activity modification |
| US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8019421B2 (en) * | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
| US8346363B2 (en) | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
| DE19952147A1 (de) | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6800618B2 (en) * | 2001-05-07 | 2004-10-05 | The United States Of America As Represented By The Secretary Of The Army | Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof |
| WO2002089810A1 (en) * | 2001-05-07 | 2002-11-14 | United States Army Medical Research And Materiel Command | Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof |
| US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AU2002352772B2 (en) * | 2001-11-21 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Chemokine receptor antagonists and methods of use thereof |
| US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
| CN1787850B (zh) * | 2003-03-10 | 2015-12-16 | 脉冲动力公司 | 用于传送电信号以修改心脏组织中基因表达的装置与方法 |
| US20070066570A1 (en) * | 2003-06-16 | 2007-03-22 | Michael Solomon | Methods for treating sleep disorders |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
| US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
| US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
| DE202004009224U1 (de) * | 2004-06-14 | 2004-08-12 | Isra Vision Systems Ag | Sensor zur Vermessung der Oberfläche eines Objekts |
| US8244371B2 (en) | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
| AU2007332867B2 (en) * | 2006-12-11 | 2012-02-16 | Merck Sharp & Dohme Corp. | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators |
| JP2010528061A (ja) | 2007-05-29 | 2010-08-19 | ジョングオケシュエユアンシャンハイヤオウヤンジュスオ | ７員環化合物及びその糖尿病と代謝症候群を治療するための薬学的用途 |
| WO2011092710A2 (en) | 2010-02-01 | 2011-08-04 | Metacure Limited | Gastrointestinal electrical therapy |
| JP2020526592A (ja) | 2017-07-13 | 2020-08-31 | トニックス ファーマシューティカルズ ホールディング コーポレーション | シクロベンザプリン類似体及びアミトリプチレン類似体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE560750A (xx) * | 1957-07-26 | |||
| ATE132486T1 (de) * | 1990-10-15 | 1996-01-15 | Pfizer | Pyrrolidin-dionderivate |
| WO1992016226A1 (en) * | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
| MY113463A (en) * | 1994-01-04 | 2002-03-30 | Novo Nordisk As | Novel heterocyclic compounds |
-
1996
- 1996-12-12 AU AU11384/97A patent/AU704825B2/en not_active Ceased
- 1996-12-12 IL IL12455796A patent/IL124557A0/xx unknown
- 1996-12-12 CA CA002239487A patent/CA2239487A1/en not_active Abandoned
- 1996-12-12 CZ CZ981795A patent/CZ179598A3/cs unknown
- 1996-12-12 EP EP96942264A patent/EP0869777A1/en active Pending
- 1996-12-12 HU HU9901652A patent/HUP9901652A3/hu unknown
- 1996-12-12 KR KR1019980704501A patent/KR20000064411A/ko not_active Application Discontinuation
- 1996-12-12 JP JP9522429A patent/JP3048067B2/ja not_active Expired - Lifetime
- 1996-12-12 WO PCT/DK1996/000524 patent/WO1997022338A1/en not_active Application Discontinuation
- 1996-12-12 PL PL96327445A patent/PL327445A1/xx unknown
- 1996-12-12 BR BR9612005A patent/BR9612005A/pt not_active Application Discontinuation
- 1996-12-13 ZA ZA9610543A patent/ZA9610543B/xx unknown
- 1996-12-13 US US08/766,839 patent/US5741791A/en not_active Expired - Fee Related
- 1996-12-13 AR ARP960105681A patent/AR005075A1/es unknown
-
1998
- 1998-06-12 NO NO982732A patent/NO982732L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US5741791A (en) | 1998-04-21 |
| PL327445A1 (en) | 1998-12-07 |
| EP0869777A1 (en) | 1998-10-14 |
| MX9804749A (es) | 1998-10-31 |
| NO982732L (no) | 1998-08-14 |
| HUP9901652A3 (en) | 2000-04-28 |
| AR005075A1 (es) | 1999-04-07 |
| BR9612005A (pt) | 1999-02-09 |
| CA2239487A1 (en) | 1997-06-26 |
| KR20000064411A (ko) | 2000-11-06 |
| JP3048067B2 (ja) | 2000-06-05 |
| NO982732D0 (no) | 1998-06-12 |
| JPH11507947A (ja) | 1999-07-13 |
| HUP9901652A2 (hu) | 1999-09-28 |
| WO1997022338A1 (en) | 1997-06-26 |
| AU704825B2 (en) | 1999-05-06 |
| IL124557A0 (en) | 1998-12-06 |
| CZ179598A3 (cs) | 1998-09-16 |
| AU1138497A (en) | 1997-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA9610543B (en) | Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP. | |
| EP0686203A4 (en) | COMPOUNDS AND METHODS RELATING TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF CELL DEATH DISEASES | |
| HUP0400694A3 (en) | Small molecule inhibitors of rotamase enzyme activity and pharmaceutical compositions containing the compounds | |
| AU9040098A (en) | Compounds and method for the prevention and treatment of diabetic retinopathy | |
| HUP9601698A3 (en) | Pharmaceutical composition of adiabetical activity | |
| ZA991716B (en) | Pharmaceutical composition of topiramate. | |
| PH31420A (en) | Methods of use for inhibiting bone loss and lowering serum cholesteol. | |
| EP0811595A4 (en) | HYDROCHALCONE DERIVATIVES, COSMETIC COMPOSITIONS CONTAINING THEM AND PROCESSES FOR PREPARING SUCH DERIVATIVES OR COMPOSITIONS | |
| GB0015235D0 (en) | Compositions for the treatment of skin and anorectal conditions | |
| IL118222A (en) | Pharmaceutical compositions for treatment of hyperglycemia and/or stabilization of serum glucose levels comprising chromic tripicolinate | |
| HUP0003851A3 (en) | Pharmaceutical composition for the treatment or prevention of glomerulopathy | |
| HK1020259A1 (en) | Composition for use in the treatment and prevention of hyperuricemia. | |
| ZA200007642B (en) | Treatment of airborne microorganisms. | |
| EP0567088A3 (en) | Process for the preparation of an amylase inhibitor. | |
| HU9502918D0 (en) | Pharmaceutical composition of antihypertriglyceridemic activity | |
| ZA966063B (en) | Synergistic herbicidal composition and method of use thereof. | |
| EP0661972A4 (en) | USE OF SPIPERONE OR SPIPERONE DERIVATIVES AS IMMUNODEPRESSANT AGENTS. | |
| EP0681787A3 (en) | Use of an enzyme for the manufacture of an agent suitable for the treatment and / or prophylaxis of coccidiosis. | |
| PL329376A1 (en) | Carbapenemic compounds exhibiting antibacterial activity, compositions containing such compounds and medical treatment methods employing such compositions | |
| AU6786898A (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders | |
| ZA976350B (en) | Treatment of liquid. | |
| AU1820499A (en) | Compounds and methods for the diagnosis and treatment of (b. microti) infection | |
| AU6786598A (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders | |
| GB9510162D0 (en) | Compositions for the treatment of skin conditions | |
| ZA9610433B (en) | Medical use of proteases. |